Carbohydrate Microarray Profiling of Glycan-Binding Antibodies and Lectins

碳水化合物结合抗体被广泛用于基础研究，并用作诊断和治疗试剂。它们在癌症领域特别有用。在疾病的发生和发展过程中，癌细胞的碳水化合物表达发生了巨大的变化。因此，人们对了解这些变化发生的原因、它们如何导致疾病以及将这些变化用于临床一直很感兴趣。例如，联合妥欣(地尼妥昔单抗)是FDA批准的针对肿瘤相关碳水化合物GD2的单抗，用于治疗儿童神经母细胞瘤。不幸的是，针对碳水化合物的好的单抗很少。缺乏高质量的抗体是该领域的一大障碍。我们正采取多管齐下的方法来帮助缓解这一问题。首先，我们使用我们的葡聚糖微阵列来评估现有的碳水化合物抗体的选择性。这一信息对于为特定应用选择正确的抗体和解释结果至关重要。其次，我们开发了一个碳水化合物抗体数据库(抗糖试剂数据库；DAGR)，可以用来寻找抗体和有关这些抗体的信息。第三，我们正在研究哺乳动物体内产生碳水化合物抗体的机制。第四，我们正在使用我们的葡聚糖微阵列来发现和设计针对碳水化合物的新抗体

Carbohydrate-binding antibodies are used extensively for basic research and are useful as diagnostic and therapeutic agents. They are especially useful in the field of cancer. Cancer cells undergo dramatic changes in carbohydrate expression during the onset and progression of disease. As a result, there has been considerable interest in understanding why these changes occur, how they contribute to the disease, and exploiting these changes for clinical use. For example, Unituxin (dinituximab) is an FDA approved monoclonal antibody that targets the tumor associated carbohydrate GD2 and is used to treat children with neuroblastoma. Unfortunately, there are very few good monoclonal antibodies to carbohydrates. The lack of high quality antibodies is a major barrier for the field. We are taking a multi-pronged approach to help alleviate this problem. First, we use our glycan microarray to evaluate the selectivities of existing antibodies to carbohydrates. This information is crucial for selecting the right antibody for a particular application and interpreting results. Second, we have developed a database of antibodies to carbohydrates (Database of Anti-Glycan Reagents; DAGR) that can be used to find antibodies and information about those antibodies. Third, we are studying the mechanisms by which antibodies to carbohydrates are produced in mammals. Fourth, we are using our glycan microarray to discover and engineer new antibodies to carbohydrates